Using [18F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 1, 2016, Pages 228-239

  McGuire, Sarah M ^a   Bhatia, Sudershan K ^a   Sun, Wenqing ^a   Jacobson, Geraldine M ^b   Menda, Yusuf ^a   Ponto, Laura L ^a   Smith, Brian J ^c   Gross, Brandie A ^a   Bayouth, John E ^d   Sunderland, John J ^a   Graham, Michael M ^a   Buatti, John M ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BONE; CELLS; CHEMORADIOTHERAPY; CHEMOTHERAPY; DISEASES; PATIENT TREATMENT; POSITRONS; RADIOTHERAPY; REGRESSION ANALYSIS; TOXICITY;

CHEMORADIATION THERAPIES; COMPLETE BLOOD COUNTS; COX REGRESSION ANALYSIS; HEMATOLOGIC TOXICITY; INTENSITY MODULATED RADIATION THERAPY; METHODS AND MATERIALS; POSITRON EMISSION TOMOGRAPHY (PET); RADIATION SENSITIVITY;

POSITRON EMISSION TOMOGRAPHY;

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; FLUOROURACIL; MITOMYCIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ANUS CANCER; ARTICLE; BLOOD CELL COUNT; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; FEBRILE NEUTROPENIA; HEMATOLOGIC TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PELVIC GIRDLE; PELVIS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION DOSE REDUCTION; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOTHERAPY PLANNING SYSTEM; RECTUM CANCER; SIMULATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXICITY; UTERINE CERVIX CANCER; ADVERSE EFFECTS; AGED; DIAGNOSTIC IMAGING; FEMALE; HEMATOLOGIC DISEASES; IMAGE GUIDED RADIOTHERAPY; MALE; MIDDLE AGED; PELVIC NEOPLASMS; PROCEDURES; RADIATION INJURIES; RADIATION PROTECTION; RADIOTHERAPY DOSAGE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CHEMORADIOTHERAPY; DIDEOXYNUCLEOSIDES; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; PELVIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION INJURIES; RADIATION PROTECTION; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, IMAGE-GUIDED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84990829200     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.04.009     Document Type: Article

References (26)

1. 1 Ellis, R.E., The distribution of active bone marrow in the adult. Phys Med Biol 5 (1961), 255–258.
2. 2 Hayman, J.A., Callahan, J.W., Herschtal, A., et al. Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. Int J Radiat Oncol Biol Phys 79 (2011), 847–852.
3. 3 Mauch, P., Constine, L., Greenberger, J., et al. Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 31 (1995), 1319–1339.
4. 4 Abu-Rustum, N.R., Lee, S., Correa, A., et al. Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer. Gynecol Oncol 81 (2001), 88–91.
5. 5 Brixey, C.J., Roeske, J.C., Lujan, A.E., et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54 (2002), 1388–1396.
6. 6 Keys, H.M., Bundy, B.N., Stehman, F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. N Engl J Med 340 (1999), 1154–1161.
7. 7 Nugent, E.K., Case, A.S., Hoff, J.T., et al. Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol 116 (2010), 438–441.
8. 8 Parker, K., Gallop-Evans, E., Hanna, L., et al. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: Results from a single institution. Int J Radiat Oncol Biol Phys 74 (2009), 140–146.
9. 9 Rose, P.G., Bundy, B.N., Watkins, E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999), 1144–1153.
10. 10 Flam, M., John, M., Pajak, T.F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14 (1996), 2527–2539.
11. 11 Hodges, J.C., Das, P., Eng, C., et al. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys 75 (2009), 791–794.
12. 12 Milano, M.T., Jani, A.B., Farrey, K.J., et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63 (2005), 354–361.
13. 13 Dipetrillo, T., Pricolo, V., Lagares-Garcia, J., et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 82 (2012), 124–129.
14. 14 Agool, A., Schot, B.W., Jager, P.L., et al. 18F-FLT PET in hematologic disorders: A novel technique to analyze the bone marrow compartment. J Nucl Med 47 (2006), 1592–1598.
15. 15 Agool, A., Slart, R.H., Thorp, K.K., et al. Effect of radiotherapy and chemotherapy on bone marrow activity: A 18F-FLT-PET study. Nucl Med Commun 32 (2011), 17–22.
16. 16 McGuire, S.M., Menda, Y., Boles Ponto, L.L., et al. 3’-Deoxy-3’-[18F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys 81 (2011), 888–893.
17. 17 Menda, Y., Boles Ponto, L.L., Dornfield, K.J., et al. Investigation of the pharmacokinetics of 3’-deoxy-3’-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol 37 (2010), 433–438.
18. 18 National Comprehensive Cancer Network. NCCN guidelines, 2015. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 1, 2016.
19. 19 Machulla, H.J., Blocher, A., Kuntzsch, M., et al. Simplified labeling approach for synthesizing 3’-deoxy-3’-[F-18]fluorothymidine ([F-18]FLT). J Radioanal Nucl Chem 243 (2000), 843–846.
20. 20 McGuire, S.M., Menda, Y., Ponto, L.L., et al. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiother Oncol 99 (2011), 49–54.
21. 21 Mell, L.K., Kochanski, J.D., Roeske, J.C., et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006), 1356–1365.
22. 22 McGuire, S.M., Menda, Y., Boles Ponto, L.L., et al. Spatial mapping of functional pelvic bone marrow using FLT PET. J Appl Clin Med Phys, 15, 2014, 4780.
23. 23 Dinges, E., Felderman, N., McGuire, S., et al. Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties. Radiother Oncol 115 (2015), 373–378.
24. 24 Song, W.Y., Huh, S.N., Liang, Y., et al. Dosimetric comparison study between intensity modulated radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer. J Appl Clin Med Phys, 11, 2010, 3255.
25. 25 Dittmann, H., Dohmen, B.M., Kehlbach, R., et al. Early changes in [18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging 29 (2002), 1462–1469.
26. 26 Muzi, M., Vesselle, H., Grierson, J.R., et al. Kinetic analysis of 3’-deoxy-3’-fluorothymidine PET studies: Validation studies in patients with lung cancer. J Nucl Med 46 (2005), 274–282.